PDGFRB and Hepatic fibrosis: The inhibition of liver fibrogenesis and angiogenesis is achieved by miR-26b-5p through its direct targeting of PDGFR-β, which may represent an effective therapeutic strategy for liver fibrosis (Yang et al., 2019).